Severe acute respiratory syndrome (SARS)—associated coronavirus diagnostics
AssigneeInstitut Pasteur
InventorsSylvie Van Der Werf, Nicolas Escriou, Caroline Demeret, Stéphane Petres, Pierre Lafaye, Jacques Bellalou
Life of this patent
Estimating the term…
Abstract
The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.
Claims18
A method for the detection of a severe acute respiratory syndrome (SARS)
- associated coronavirus infection in a biological sample comprising:
- providing a severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein expressed and purified from E. coli strain BL21 (DE3) pDIA17 transformed with recombinant plasmid pETM11/N-nCov E. coli 3-(His)6-Nter or pETM11/N-nCov E. coli 4-(His)6-Nter deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) at the Institut Pasteur, 25, Rue du Docteur Roux, 75724 Paris, FR, on May 11, 2020, under the deposit numbers CNCM 1-5510 and CNCM 1-5511, respectively;
- providing a biological sample from an individual or a patient suspected to be infected with a severe acute respiratory syndrome-associated coronavirus (SARS-CoV) coronavirus;
- contacting said SARS-CoV-2 N protein with said biological sample;
- and
- visualizing the antigen-antibody complexes formed.
A method for the detection of a SARS-associated coronavirus infection in a biological sample comprising:
- providing a SARS-CoV-1 N protein and a SARS-CoV-2 N protein,
- wherein said SARS-CoV-2 N protein is expressed and purified from E. coli strain BL21 (DE3) PDIA17 transformed with recombinant plasmid PETM11/N-nCov E. coli 3-(His)6-Nter or pETM11/N-nCov E. coli 4-(His)6-Nter deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) at the Institut Pasteur, 25, Rue du Docteur Roux, 75724 Pars, FR, on May 11, 2020, under the deposit numbers CNCM I-5510 and CNCM 1-5511, respectively:
- providing a biological sample from an individual or a patient suspected to be infected with a coronavirus:
- contacting said SARS-CoV-1 N and SARS-CoV-2 N proteins with said biological sample;
- and
- visualizing the antigen-antibody complexes formed.
A kit for the detection of a SARS-CoV coronavirus infection in a biological sample comprising a SARS-CoV-2 N protein expressed and purified from E. coli BL21 (DE3) pDIA17 transformed with recombinant plasmid pETM11/N-nCov E. coli 3-(His)6-Nter or pETM11/N-nCov E. coli 4-(His)6-Nter deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) at the Institut Pasteur, 25, Rue du Docteur Roux, 75724 Paris, FR, on May 11, 2020, under the deposit numbers CNCM 1-5510 and CNCM 1-5511, respectively.
A method for producing a SARS-CoV-2 N protein comprising the following steps:
- Culturing a bacterium transformed with a recombinant plasmid encoding for a SARS-CoV-2 N protein deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) at the Institut Pasteur, 25, Rue du Docteur Roux, 75724 Paris, FR, on May 11, 2020, under the deposit number CNCM 1-5510 or the deposit number CNCM 1-5511 in a suitable bacterial growth medium;
- inducing the production of SARS-CoV-2 N protein;
- recovering and purifying SARS-CoV-2 N protein.
Dependencies are inferred from the claim text.